Michael A. Cannarile

Author

Also Known As

Cannarile, Michael Angelo, M. Cannarile, M.A. Cannarile, Michael A Cannarile, Michael A. Cannarile, Michael Cannarile, Michael A. Cannarile

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Roche Pharma AG (Germany)Centre Léon Bérard Institut Claudius Regaud Roche (United Kingdom)

About

Michael A. Cannarile is an author at Roche (Switzerland) specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	2.4K
2	Immunology	8	8	2.4K
3	Pathology	4	4	442
4	Cell Biology	3	3	480
5	Rheumatology	1	1	11

Michael A. Cannarile

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy Carola H. Ries, Michael A. Cannarile, Sabine Hoves, Cancer Cell Cancer TherapyTumor BiologyTumor-associated MacrophagesTumor ImmunologyCancer Immunosurveillance	2014	1.3K
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca, The Lancet Oncology MedicineImmunologyPathologySoft TissueImmune Checkpoint Inhibitor	2015	356
Transcriptional regulator Id2 mediates CD8+ T cell immunity Michael A. Cannarile, Nicholas A. Lind, Richard Rivera, Nature Immunology Adaptive Immune SystemImmunologyAutoimmunityT Cell ImmunityTranscriptional Regulator Id2	2006	247
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity Sabine Hoves, Chia-Huey Ooi, Carsten Wolter, The Journal of Experimental Medicine Rapid ActivationImmune EvasionCancer ImmunosurveillanceT-regulatory CellImmunology	2018	205
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages C. Gomez-Roca, Antoîne Italiano, Christophe Le Tourneau, Annals of Oncology Immunosuppressive M2-like MacrophagesMedicineMetronomic TherapyImmunologyEmactuzumab Single Agent	2019	189
Cutting Edge: Dendritic Cells Are Sufficient to Cross-Present Self-Antigens to CD8 T Cells In Vivo Christian Kurts, Michael A. Cannarile, Ina Klebba, The Journal of Immunology	2001	179
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors C. Willemien Menke‐van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, Oncotarget	2016	148
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin, Journal for ImmunoTherapy of Cancer	2022	93
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients Jean‐Pascal Machiels, Carlos Gomez‐Roca, Jean‐Marie Michot, Journal for ImmunoTherapy of Cancer	2020	72
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment Leon P. Pradel, Chia-Huey Ooi, Solange Romagnoli, Molecular Cancer Therapeutics	2016	71

Page 1